Email Updates

You are here

AVAC's Blog: P-Values

  • On the heels of Wednesday’s announcement from Janssen Pharmaceutical Company that the Mosaico HIV vaccine trial is ending for lack of efficacy, there’s much to learn and discuss. Please join AVAC and the HIV Vaccine Trials Network (HVTN) for a webinar on January 25th at 9am PST/12pm EST/6pm CET. The webinar will include study investigators and community representatives as we all discuss the outcome of the Mosaico study, what these results mean and next steps. Register here.

    January 20, 2023
  • The Mosaico study, a large-scale HIV vaccine efficacy study also known as HVTN 706/HPX3002, was stopped early for non-efficacy. An independent data and safety monitoring board, at a scheduled review of the trial data, found the regimen to be safe, but that it did not meet the pre-defined criteria for efficacy and recommended that the study be stopped and trial participants informed.

    January 18, 2023
  • AVAC is excited to launch the Advocacy Navigator, an extension of our Advocacy Fellows program, which has involved more than 90 advocates and dozens of civil society organizations in 15 countries to drive groundbreaking advocacy on HIV prevention research, rollout, and human rights. AVAC now seeks applications from early-career professionals from Eastern and Southern Africa interested in strengthening their skills in HIV prevention advocacy.

    January 17, 2023
  • At AVAC we saw tremendous work to accelerate HIV prevention and invest in global health resilience in 2022, and the year ahead will require critical advocacy to keep the field on track. What does this mean? Our year-end letter, HIV Prevention and Equity in 2022 & Beyond, explores in depth the many initiatives, resources and collaborations that powered advocacy in 2022 — a historic juncture for HIV and global health.

    January 11, 2023
  • This year was an incredible one of reflection, engagement, opportunity, and action. More than 40 years into the HIV epidemic – and in the midst of multiple other pandemics and persistent inequities – AVAC and its partners continue to reshape, reimagine and fight for effective HIV prevention.

    December 21, 2022
  • World AIDS Day is a day to remember and reflect, but it can also be a day to intensify advocacy, which was the case for many of our 2022 AVAC Advocacy Fellows. From broadcast interviews, to an open forum on religion and sexuality, to a symposium attended by the Prime Minister of Lesotho, AVAC Fellows took World AIDS Day to task with a day of conversation and advocacy. Check out highlights from the day below.

    December 15, 2022
  • The Choice Agenda (TCA), a global forum for advocacy on HIV prevention, is just a few new sign ups away from the 1,000 member mark!!! It’s a milestone reminding us of what the TCA has achieved in such a short time, with agenda-setting conversations and deep-dive webinars on key issues in the field and a full program to come in 2023.

    December 12, 2022
  • New research published in the journal PLOS today from AVAC and COMPASS partners shows the importance and value of an enabling policy environment to increase the uptake of HIV prevention services, including for PrEP.

    December 7, 2022
  • Coming off World AIDS Day, we are reminded of the importance of robust domestic investment in all aspects of the HIV response, including research and development (R&D), to see an end to the epidemic and build sustainable systems for health.

    December 6, 2022
  • Each World AIDS Day is an opportunity to reflect, remember and, hopefully, reenergize. This year is no different, but, more than 40 years into this epidemic – and in the midst of multiple other pandemics and persistent inequities – this could be the year that marks a fundamental reshaping and reimagination of HIV prevention, if everyone does their part.

    December 1, 2022